Tyme Technologies, Inc. is a biotech firm that is focused on developing cancer metabolism-based treatments that have low toxicity and can be effective for various kinds of tumors. The firm's approach leverages the innate weaknesses of cancer cells to lower their defenses, making them more susceptible to oxidative stress and the body's immune system response. This is different from targeted therapies that aim to regulate specific mutations in cancer. Tyme's strategy has shown promise in preclinical studies, and the firm is hoping to advance its research and development efforts in the coming years.
Tyme's ticker is TYME
The company's shares trade on the NASDAQ stock exchange
They are based in New York City, New York
There are 11-50 employees working at Tyme
It is tymeinc.com/about-tyme/tyme-overview/default.aspx
Tyme is in the Healthcare sector
Tyme is in the Biotechnology industry
The following five companies are Tyme's industry peers: